Autonomix Medical reports $5.1M cash position
Autonomix Medical, Inc. reported that as of July 28, 2026, its cash balance was approximately $5.1 million and it had 971,043 shares of common stock outstanding.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Autonomix Medical, Inc. reported that as of July 28, 2026, its cash balance was approximately $5.1 million and it had 971,043 shares of common stock outstanding.
The outstanding share count includes common shares issued in connection with a warrant inducement dated July 13, 2026, providing an updated snapshot of the company’s cash position and capital structure.
Insights
Analyzing...
8-K Event Classification
Item 8.01 — Other Events
1 item
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Key Figures
Cash balance: approximately $5.1 million
Common shares outstanding: 971,043 shares
Par value per common share: $0.001 per share
3 metrics
Cash balance
approximately $5.1 million
As of July 28, 2026
Common shares outstanding
971,043 shares
As of July 28, 2026
Par value per common share
$0.001 per share
Stated par value of common stock
Key Terms
warrant inducement, emerging growth company, par value
3 terms
warrant inducement financial
"including shares of common stock issued as part of the Company’s recent warrant inducement"
Warrant inducement is when a company offers new warrants—options to buy shares at a set price—as a sweetener to persuade investors, lenders, or shareholders to approve a deal or provide financing. Investors should care because these extra warrants can dilute existing ownership if exercised, change the company’s future share supply and potential upside, and alter the risk/reward balance much like giving a coupon that could reduce future prices for original buyers.
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
par value financial
"Common Stock , par value $0.001 per share"
Par value is the fixed amount printed on a bond or stock that represents its original value when issued. It’s like the face value of a coin or bill—what the issuer promises to pay back or the starting price of a stock—though it often doesn’t change with market prices. It matters because it helps determine certain financial details, like how much the company will pay back at maturity.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What cash balance did Autonomix Medical (AMIX) report as of July 28, 2026?
Autonomix Medical reported a cash balance of approximately $5.1 million as of July 28, 2026. This figure represents the company’s available cash on that date and accompanies an updated disclosure of its outstanding common shares for investors monitoring liquidity and share count.
What did Autonomix Medical (AMIX) disclose about its recent warrant inducement?
Autonomix Medical stated that its 971,043 outstanding common shares include stock issued in connection with a warrant inducement dated July 13, 2026. This links the updated share count to a recent warrant-related transaction affecting the company’s capital structure.
What is the par value of Autonomix Medical (AMIX) common stock?
Autonomix Medical’s common stock has a stated par value of $0.001 per share. While par value is largely an accounting concept, it defines the nominal value assigned to each share in the company’s charter and appears in corporate and financial disclosures.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 28, 2026
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation or organization) | (Commission File Number) | (I.R.S. Employer Identification No.) |
(Address of principal executive offices) (Zip Code)
Registrant’s telephone number, including area code: (713 ) 588-6150
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class | Trading Symbol(s) | Name of Each Exchange on which Registered |
The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01. Other Events
As of July 28, 2026, Autonomix Medical, Inc.’s (the “Company”) cash balance is approximately $5.1 million and shares of the Company’s common stock outstanding is 971,043, including shares of common stock issued as part of the Company’s recent warrant inducement from July 13, 2026.
Signature
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
AUTONOMIX MEDICAL, INC. | |||
By: | /s/ Trent Smith | ||
Trent Smith | |||
Chief Financial Officer | |||
Dated: July 28, 2026